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Abstract
Introduction: The prevalence of comorbidities in incident
renal replacement therapy (RRT) patients changes with
age and varies between ethnic groups. This study
describes these associations and the independent effect
of comorbidities on outcomes. Methods: Adult patients
starting RRT between 2003 and 2008 in centres reporting
to the UK Renal Registry (UKRR) with data on comorbidity
(n¼ 14,909) were included. The UKRR studied the association
of comorbidity with patient demographics, treatment
modality, haemoglobin, renal function at start of RRT and
subsequent listing for kidney transplantation. The relation-
ship between comorbidities and mortality at 90 days and
one year after 90 days from start of RRT was explored
using Cox regression. Results: Completeness of comorbidity
data was 40.0% compared with 54.3% in 2003. Of patients
with data, 53.8% had one or more comorbidities. Diabetes
mellitus and ischaemic heart disease were the most
common conditions seen in 30.1% and 22.7% of patients
respectively. Current smoking was recorded for 14.5% of
incident RRT patients in the 6-year period. Comorbidities
became more common with increasing age in all ethnic
groups although the difference between the 65–74 and
75þ age groups was not signiﬁcant. Within each age
group, South Asians and Blacks had lower rates of comorbid-
ity, despite higher rates of diabetes mellitus. In multivariate
survival analysis, malignancy and ischaemic/neuropathic
ulcers were the strongest independent predictors of poor
survival at 1 year after 90 days from the start of RRT. Con-
clusion: Differences in prevalence of comorbid illnesses in
incident RRT patients may reﬂect variation in access to
health care or competing risk prior to commencing treatment.
At the same time, smoking rates remained high in this ‘at risk’
population. Further work on this and ways to improve
comorbidity reporting should be priorities for 2010–11.
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Introduction
The importance of adjusting for comorbidity in centre
[1, 2] and international survival comparisons [3] has
long been recognised and evidence of its importance in
anaemia [4], hospitalisation [5–7] healthcare costs [5]
and quality of life [8] is emerging. As with all observa-
tional data, registry analyses for purposes of epidemiology,
access to treatment or quality control, are open to a
number of selection biases. Therefore, registry analyses
can be significantly strengthened by adjustment for case
mix, as differences in patient populations that exist
across centres may affect process and outcome measures.
The aim of this chapter is to describe the prevalence of
comorbid conditions and current smoking status in
incident renal replacement therapy (RRT) patients
reported to the UK Renal Registry (UKRR) and to
examine the association between these comorbidities
and early mortality.
The term established renal failure (ERF) used
throughout this chapter is synonymous with the terms
of end stage renal failure (ESRF) and end stage renal
disease (ESRD), which are widely used internationally.
Within the UK, patient groups have disliked the term
‘end stage’ due to its reference to the inevitable outcome
of this disease.
Methods
Study population
Incident adult (518 years) RRT patients (n¼ 32,356) between
2003 and 2008 in the centres submitting data to the UKRR were
considered. Of these, patients who had data on comorbidity
were included (n¼ 14,909; 46.1%). Data on completeness of
comorbidity returns from each centre and overall may differ
from those in previous UKRR reports due to some centres
retrospectively entering previously missing comorbidity data.
Centre exclusions
The nine centres in Scotland do not provide comorbidity data
to the UKRR and are not included in these analyses. There was
concern that data extraction in two centres (Stoke and Colchester)
was inaccurate and these centres were excluded from this year’s
analyses.
Definition of comorbidity and method of data collection
Clinical staff in each centre are responsible for recording (in
yes/no format), on their renal information technology (IT)
system, the presence or absence of 13 comorbid conditions and
information on current tobacco smoking (table 6.1) for each
patient at the time of starting RRT. Definitions of each of these
conditions are given in appendix B. Patients were classified as
having complete comorbidity data if there was at least one entry
(yes/no) for any one or more of the comorbid conditions.
Comorbidities were grouped into broader categories for some
analyses:
. ‘Ischaemic heart disease’ was defined as the presence of one
or more of the following conditions: angina, myocardial
infarction (MI) in the three months prior to starting RRT,
MI more than three months prior to starting RRT or coron-
ary artery bypass grafting (CABG)/angioplasty.
. ‘Peripheral vascular disease’ was defined as the presence of
one or more of the following conditions: claudication,
ischaemic or neuropathic ulcers, non-coronary angioplasty,
vascular graft, aneurysm or amputation for peripheral
vascular disease.
. ‘Non-coronary vascular disease’ was defined as the presence
of cerebrovascular disease or any of the data items that
comprise ‘peripheral vascular disease’.
Ethnicity data reporting
Some centres electronically upload ethnicity coding to their
renal IT system from the hospital Patient Administration Systems
(PAS) [9]. Ethnicity coding in PAS is based on self-reported eth-
nicity and uses a different system [10] to the remaining centres
where ethnic coding is performed by clinical staff and recorded
directly into the renal IT system (using a variety of coding sys-
tems). For all these analyses, data on ethnic origin were grouped
into Whites, South Asians, Blacks and Others. Appendix G details
the regrouping of the PAS codes into the above ethnic categories.
Statistical methods
The statistical methods for the four individual sections of this
chapter are described separately. The number of patients with data
Table 6.1. Comorbid conditions listed in the UKRR dataset
Comorbidity
. Angina
. Previous myocardial infarction (MI) within 3 months prior to
start of RRT
. Previous MI more than 3 months prior to start of RRT
. Previous coronary artery bypass graft (CABG) or coronary
angioplasty
(in some analyses the above four variables are combined
under the term ‘ischaemic heart disease’)
. Cerebrovascular disease
. Diabetes (when not listed as the primary renal disease)
. Chronic obstructive pulmonary disease (COPD)
. Liver disease
. Claudication
. Ischaemic or neuropathic ulcers
. Non-coronary angioplasty, vascular graft, or aneurysm
. Amputation for peripheral vascular disease
(in some analyses these four variables are combined under
the term ‘peripheral vascular disease’)
. Smoking
. Malignancy
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on comorbidity and other variables included in the analyses are
summarised in figure 6.1.
1) Patient demographics
The proportion of patients starting RRT with various
comorbidities was examined by age group (18–34, 35–44,
45–54, 55–64, 65–74 and 575 years), primary renal disease,
ethnic origin and first modality of RRT. Chi-squared, Fischer’s
exact and Kruskal Wallis tests were used as appropriate to test
for significant differences between groups.
2) Late presentation (referral), haemoglobin (Hb) and renal
function at start of RRT
Referral time was defined as the number of days between
the date first seen by a nephrologist and the date of starting
RRT. Referral times of more than 90 days and less than 90
days define early and late presentation, respectively. Data on
referral time was incomplete and therefore only patients with
data on comorbidity and referral time from centres with
>75% data completeness for referral time were included in
this analysis (n¼ 6,714; 20.8% of all patients starting RRT).
The association of various comorbidities with Hb concen-
tration at start of RRT was studied amongst patients with
comorbidity data and Hb data within 14 days before the
start of RRT (n¼ 9,447; 29.2% of all patients starting RRT).
Two-sample t-tests were used to compare the mean Hb at
start of RRT amongst patients with each specific comorbidity
with the mean for those with none of the comorbidities. As
many tests were carried out, only p values <0.01 were consid-
ered statistically significant for these analyses.
The association of various comorbidities with estimated
glomerular filtration rate (eGFR) at start of RRT was studied
amongst patients with comorbidity data and eGFR data
within 14 days before the start of RRT. The eGFR was calcu-
lated using the abbreviated 4 variable MDRD study equation
[11]. For the purpose of eGFR calculation, patients who had
missing ethnicity but a valid serum creatinine measurement
were classed as White as the Black population only account
for 6% of the total UK RRT population. The eGFR values
were log transformed in order to normalise the data and
then two-sample t-tests were used to compare the means of
the log eGFR of those patients with each specific comorbidity
against those with none of the comorbidities present. As many
statistical tests were carried out, only p values <0.01 were
considered statistically significant for these analyses.
There is no defined eGFR at which patients should start
RRT and a number of factors, including clinical presentation,
symptoms, complications of uraemia and biochemistry, are
used to determine dialysis initiation. However, there are
defined eGFR thresholds for pre-emptive listing for a kidney
transplant. The European Best Practice Guidelines (EBPG)
recommend that patients with progressive irreversible
deterioration in renal function and a creatinine clearance of
<15ml/min/1.73 m2 should be considered for pre-emptive
transplantation; patients with ERF secondary to diabetes
should be considered for early and pre-emptive transplanta-
tion when their eGFR decreases to <20 ml/min/1.73 m2 [12].
In the UK, the British Transplantation Society (www.bts.
org.uk) endorse the EBPG and current UK Renal Association
guidelines recommend that patients should be placed on the
kidney transplant waiting list within six months of their
anticipated dialysis start date [13]. There are no KDOQI
guidelines for listing. It is therefore possible that patients
could have started RRT with a transplant and an eGFR value
as high as 20 ml/min/1.73 m2.
For the eGFR analyses, 14,909 patients with comorbidity
data were considered for inclusion. Patients with no eGFR
data (n¼ 2,632) were excluded, as were those with no eGFR
data in the 14 days preceding RRT (n¼ 2,056). Patients with
an eGFR >20 ml/min/1.73 m2 (n¼ 500) were excluded from
the eGFR analyses due to concerns about possible data extrac-
tion errors. Patients starting RRT between 2003 and 2005 from
one centre (London West) were also excluded due to errors in
the software data extraction process for this item (n¼ 319).
This left 9,402 (29.1% of all patients starting RRT) eligible
for analysis. Many UKRR analyses, including those presented
here, rely on the accuracy of the date of start of RRT. A discus-
sion of the issues around definition of the start date is included
in chapter 13.
3) Activation on deceased donor kidney transplant waiting list
The association between comorbidity and activation on the
Primary renal
disease
N= 14,635
eGFR data
N = 9,402
Waiting list analysis:
Incident cohort (2003–2007)
N = 25,363 
Comorbidity reported
N = 12,181Ethnicity data
N= 12,943
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N = 9,447
Incident RRT (2003–2008)
in England, Wales &
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Fig. 6.1. Flow chart showing number of
patients included in the various analyses
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deceased donor kidney transplant waiting list within one year
of starting treatment was examined (n¼ 12,181). In order to
allow a year of follow up, incident patients in 2008 were not
included. Date of first activation on the waiting list for all
patients on the UKRR database starting RRT (HD or PD)
between 2003 and 2007 were obtained from NHS Blood and
Transplant, the organisation responsible for maintaining the
national organ donor register. All patients were followed
until 31st December 2008 to determine the date of activation
on the waiting list. The prevalence of various comorbidities
amongst patients activated on the waiting list within the first
year of RRT was compared with those activated on the waiting
list beyond the first year or not activated within the follow-up
period. Patients who died within the first year and were not on
the active waiting list at the time of death were included under
the ‘non-waitlisted’ group.
4) Patient survival
The Registry collected data with a ‘timeline’ entry on all
patients who had started RRT for ERF. Patients presenting
acutely and initially classified as acute renal failure requiring
dialysis who continued to require long-term dialysis, can be
re-classified by clinicians as having had ERF from the date of
their first RRT. The death rate is high in the first 90 days and
variable between centres, due partly to individual clinical var-
iation in the classification of patients with acute kidney injury
who may be deemed from the start to be unlikely to recover
renal function. To remove this centre variation and allow
comparison with results from other national registries, the
association of comorbid conditions and survival 1 year after
90 days from start of RRT was also analysed.
For each of the follow up periods, the association of
baseline comorbidity with survival was studied using uni-
variate and multivariate Cox regression models. For analyses
of survival within the first 90 days, the cohort included patients
starting RRT between 1st January 2003 and 30th September
2008 to allow a minimum of three months follow-up from
the start of RRT. For the 1 year after 90 days survival analyses,
the cohort included patients who survived at least 90 days on
RRT and who started RRT between 1st January 2003 and 30th
September 2007.
For each variable, the models were used to estimate the
hazard ratio of death, comparing patients with a particular
comorbidity with those who did not have the comorbidity.
For both the univariate and multivariate Cox models,
patients were first stratified by age group (<65 years and
565 years) to account for the increasing incidence of certain
comorbidities with age, which may otherwise obscure the
analyses. The multivariate models used an automatic selec-
tion procedure to identify the variables most strongly related
to survival. The potential variables to be included were: age
(per 10 year increase), angina, MI within 3 months prior to
starting RRT, MI more than 3 months prior to starting RRT,
coronary artery bypass grafting (CABG) or coronary angio-
plasty, cerebrovascular disease, diabetes mellitus (whether as
a cause of primary renal disease or as a comorbidity),
chronic obstructive pulmonary disease (COPD), liver disease,
claudication, ischaemic/neuropathic ulcers, angioplasty/
vascular graft, smoking and malignancy. The automatic pro-
cedure starts by including only the variable most strongly
related to survival. Then, with that variable included, it fits
models adding each of the remaining variables in turn
(singly) and chooses the variable that adds most to the
model (in addition to the contribution made by the first
variable included). The process continues in this way, adding
variables that make a further significant contribution to the
model, and removing any whose contribution becomes non-
significant once other variables have been added. The final
model only includes those variables selected by the process.
These automatic methods have been used to give an indica-
tion of the variables most strongly related to survival but
caution is needed in interpreting them because, amongst
other things, when using correlated variables, a slight differ-
ence in the data (or in the algorithm chosen) could result in
different variables being included in the final models. A
better analysis would make a considered judgement of which
variables should be included (rather than an automatic one)
and would use interaction terms and/or adjustments other
than age.
All statistical analyses were performed using SAS version 9.1.3.
Results
Completeness of comorbidity returns from each
participating centre
Of the 6,107 patients commencing RRT in centres in
England, Wales and Northern Ireland in 2008, co-
morbidity data were provided for 2,442 (40.0%) (tables
6.2 and 6.3). Table 6.2 highlights the continued wide
variation in the completeness of data returns with 4
centres providing data on 100% of patients, but 19
centres providing data for less than 5% of their new
patients in 2008.
Limiting the analysis to only the centres that reported
in 2003, data completeness for comorbidity has fallen
from 54.3% in 2003 to 43.8% in 2008. When centres
with 0% completeness for comorbidity were excluded,
the median percentage of comorbidity returns in 2008
was 52%.
Prevalence of multiple comorbidity
Including all incident patients from the years
2003–2008 (n¼ 32,356), comorbidity data were available
for 14,909 (46.1%). More than half of these patients had
one or more comorbidities (53.8%) (table 6.4) but in the
subgroup of patients aged 65 years and over, 66.1% had
one or more comorbidities (table 6.5).
Frequency of each comorbid condition
Table 6.5 lists the prevalence of specific comorbidities
and the percentage this is of the total number of incident
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Table 6.2. Completeness of comorbidity data returns on incident patients from individual centres (2003–2008)
2003 2004 2005 2006 2007 2008
Centre N % return N % return N % return N % return N % return N % return
Antrim 42 5 33 9 36 14 41 73
B Heart 103 0 102 0 116 1 115 0 101 1 108 0
B QEH 194 1 196 1 186 0 222 1 271 0
Bangor 33 48 36 64 40 55 42 60 36 64 42 57
Basldn 53 45 46 39 28 57 45 82 39 77 40 98
Belfast 130 15 112 14 89 28 68 46
Bradfd 74 85 62 92 66 95 50 100 87 99 59 92
Brightn 118 1 110 2 130 2 117 1 116 1
Bristol 163 87 163 80 175 81 176 97 154 84 181 62
Camb 94 1 107 1 110 1 156 1 125 0 102 1
Cardff 161 0 185 5 181 19 205 4 220 1 153 1
Carlis 31 29 29 79 32 94 27 93 26 92 31 97
Carsh 199 33 168 41 178 47 185 56 195 69 212 61
Chelms 49 47 37 49 48 83 51 55 33 79
Clwyd 11 0 14 0 27 4 18 0 23 4 13 0
Colchr 47 0
Covnt 75 1 76 0 83 0 102 2 110 0 113 0
Derby 60 75 67 82 71 92 70 89 61 98 92 91
Derry 3 67 7 43 6 67
Donc 18 94 25 28
Dorset 66 98 60 100 47 98 53 100 59 95 84 83
Dudley 41 0 54 0 38 0 44 2 39 0 49 0
Exeter 97 54 109 46 111 32 105 28 125 7 134 3
Glouc 53 87 54 89 60 97 73 88 58 95 45 91
Hull 80 90 108 86 126 98 100 96 99 98 117 83
Ipswi 37 43 45 47 58 31 42 62 39 49 38 34
Kent 172 5 132 29
L Barts 185 78 185 90 187 81 210 82 201 69
L Guys 93 3 100 4 128 6 132 3 162 6 169 1
L Kings 108 100 114 98 136 99 113 100 126 100 151 100
L Rfree 131 2 210 1 184 0 160 1
L St.G 89 64 89 57
L West 268 63 290 70 309 55 316 60 276 58 317 48
Leeds 185 86 178 82 161 71 172 73 125 74 155 65
Leic 167 96 162 94 226 64 242 66 244 72 215 73
Liv Ain 3 0 29 3 34 0 35 3 42 0
Liv RI 114 62 130 62 139 63 139 53 114 51 103 32
M Hope 143 33 111 42 112 35 130 12 107 8 112 1
M RI 155 23 136 34
Middlbr 103 99 101 91 84 90 109 70 99 55 93 81
Newc 109 5 114 1 101 2 85 1 107 2 101 2
Newry 28 14 13 23 15 27 20 100
Norwch 94 5 118 8 106 12 106 9 92 76
Nottm 115 98 107 95 145 99 137 98 128 94 117 44
Oxford 186 60 170 65 155 52 157 13 145 85 146 28
Plymth 64 28 62 44 58 47 91 63 76 74 70 31
Ports 140 64 117 68 151 62 174 63 157 64 169 34
Prestn 97 1 79 0 118 0 121 1 129 0 112 0
Redng 65 0 60 0 79 1 75 0 93 1 99 1
Sheff 159 65 167 59 157 41 168 58 166 55 180 45
Shrew 55 0 42 0 54 0 55 4 62 13
Stevng 123 7 83 7 92 9 121 7 88 22 101 39
Sthend 42 67 39 79 34 74 47 96 35 97 35 69
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patients for whom data was available for that item.
Diabetes mellitus (either listed as cause of PRD or as a
comorbidity) was present in 30.1% of all patients.
Ischaemic heart disease, cerebrovascular disease and
claudication were more prevalent in patients 65 years
and over. Liver disease, ischaemic/neuropathic ulcers
and prior amputation were more frequently observed
in younger patients; actual percentages, nevertheless,
were quite small (table 6.5). Smoking was also more
common amongst patients under 65 years. This broad
stratification is quite misleading however, as prevalence
of comorbidities increased markedly from 18–65 years
(figures 6.2 and 6.3).
Prevalence of comorbidity by age band
Figures 6.2 and 6.3 illustrate the increasing prevalence
of comorbidity with increasing age up to the 65–74 year
age group in incident RRT patients. In those patients
aged >75 years there was a levelling off or slight reduc-
tion of most reported comorbidities.
Prevalence of comorbidity by ethnic origin
Figure 6.4 illustrates the presence of comorbidity by
ethnic origin, showing a higher prevalence of having at
least one comorbidity amongst patients of White origin
Table 6.2. Continued
2003 2004 2005 2006 2007 2008
Centre N % return N % return N % return N % return N % return N % return
Stoke 87 3 84 0
Sund 55 69 50 96 59 93 56 93 62 100 44 100
Swanse 134 97 95 93 98 97 115 97 128 98 120 86
Truro 53 83 67 81 32 88 50 78 46 91 39 36
Tyrone 23 30 30 50 22 41 25 52
Ulster 9 56 8 63 15 100 13 100
Wirral 52 13 66 14 59 7 53 0 53 0 41 5
Wolve 88 100 105 98 92 85 87 83 67 85 87 76
Wrexm 32 3 29 0 41 0 27 0 27 4 22 45
York 57 84 48 92 43 91 48 90 35 83 33 36
Totals 4,183 4,827 5,436 5,727 6,076 6,107
Blank cells – no data returned to the UKRR for that year
Table 6.3. Summary of completeness of incident patient comorbidity returns (2003–2008)
Years Combined
years
2003 2004 2005 2006 2007 2008
Number of renal centres included 43 50 56 57 62 63
Total number of new patients 4,183 4,827 5,436 5,727 6,076 6,107 32,356
Number of patients with comorbid data entries 2,271 2,470 2,498 2,555 2,673 2,442 14,909
Percentage 54.3 51.2 46.0 44.6 44.0 40.0 46.1
Percentage restricted to centres reporting since 2003 54.3 55.6 51.6 50.0 51.4 43.8 51.0
Percentage with comorbidity returns
Median percentage amongst only centres returning >0%
comorbidity
63.7 67.5 52.3 62.5 56.6 52.0 60.2
Table 6.4. Number of reported comorbidities in patients starting
RRT, as a percentage of those for whom comorbidity data were
available (2003–2008)
Number of
comorbidities 0 1 2 3 4 5þ
Percentage 46.2 27.2 12.7 7.6 3.8 2.4
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compared to the ethnic minority. At all ages, incident
White RRT patients have more comorbidity than
incident South Asian or Black patients (figure 6.5).
This difference appears significant for Blacks at all ages
above 18–34 (figure 6.5). This difference is attributable
to lower rates of ischaemic heart disease, cerebrovascular
disease, peripheral vascular disease and malignancy with
lower rates of smoking but higher rates of diabetes
mellitus (table 6.6). Despite rates of diabetes mellitus
almost twice as high in South Asian patients (48.5%)
compared to Whites (27.3%), ischaemic heart disease
rates are similar and cerebrovascular disease rates and
peripheral vascular disease rates are slightly lower in
South Asians (table 6.6).
Prevalence of comorbidity amongst patients with
diabetes mellitus
Table 6.7 compares comorbidity amongst patients
with and without diabetes (as either primary renal
Table 6.5. Frequency with which each condition was reported in incident RRT patients 2003–2008
Age <65 years Age565 years % overall
Comorbidity N (%) N (%) p value* prevalence
Any comorbidity present 3,305 (42.5) 4,710 (66.1) <0.0001 53.8
Angina 695 (9.0) 1,567 (22.2) <0.0001 15.3
MI in past 3 months 127 (1.6) 264 (3.7) <0.0001 2.6
MI > 3 months ago 506 (6.5) 1,125 (15.9) <0.0001 11.0
CABG/angioplasty 408 (5.3) 694 (9.9) <0.0001 7.5
Cerebrovascular disease 459 (5.9) 958 (13.5) <0.0001 9.6
Diabetes (not listed as PRD) 387 (5.1) 791 (11.3) <0.0001 8.1
Diabetes listed as PRD 1,955 (25.1) 1,321 (18.6) <0.0001 22.0
COPD 312 (4.1) 689 (9.8) <0.0001 6.8
Liver disease 252 (3.3) 130 (1.8) <0.0001 2.6
Claudication 363 (4.7) 779 (11.0) <0.0001 7.7
Ischaemic/neuropathic ulcers 282 (3.6) 190 (2.7) 0.0009 3.2
Angioplasty/vascular graft 140 (1.8) 362 (5.1) <0.0001 3.4
Amputation 181 (2.3) 105 (1.5) 0.0002 1.9
Smoking 1,289 (17.0) 815 (11.9) <0.0001 14.5
Malignancy 480 (6.2) 1,218 (17.2) <0.0001 11.4
* p values from Chi-squared tests for differences between age groups in the percentage with the comorbidity
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Table 6.6. Prevalence of comorbidities amongst incident patients starting RRT 2003–2008 by ethnic group, as percentages of the total
number of patients in that ethnic group for whom comorbidity data was available
No. of patients (%) with comorbidity
White South Asian Black Other p value*
Ischaemic heart disease 2,453 (23.7) 307 (25.0) 77 (9.9) 46 (11.6) <0.0001
Cerebrovascular disease 1,029 (9.9) 106 (8.5) 67 (8.6) 25 (6.2) 0.03
Diabetes (not listed as PRD) 803 (7.8) 114 (9.4) 42 (5.4) 26 (6.5) 0.01
Diabetes listed as PRD 2,044 (19.5) 491 (39.1) 241 (30.5) 124 (30.5) <0.0001
COPD 780 (7.5) 45 (3.7) 20 (2.6) 9 (2.3) <0.0001
Liver disease 247 (2.4) 50 (4.0) 29 (3.7) 14 (3.5) 0.001
Peripheral vascular disease 1,298 (12.5) 97 (7.8) 38 (4.9) 28 (7.0) <0.0001
Smoking 1,663 (16.3) 60 (5.0) 40 (5.2) 38 (10.0) <0.0001
Malignancy 1,331 (12.7) 37 (3.0) 53 (6.8) 19 (4.7) <0.0001
* p values from Chi-squared tests for differences between ethnic groups in the percentage with the comorbidities
Table 6.7. Number and percentage of patients with and without diabetes (either as primary diagnosis or comorbidity) who have other
comorbid conditions
Non-diabetic patients Diabetic patients
Comorbidity N (%) N (%) p value*
Ischaemic heart disease 1,842 (18.3) 1,424 (32.4) <0.0001
Cerebrovascular disease 795 (7.9) 591 (13.3) <0.0001
COPD 697 (6.9) 283 (6.4) 0.3
Liver disease 240 (2.4) 130 (2.9) 0.1
Peripheral vascular disease 755 (7.5) 902 (20.4) <0.0001
Smoking 1,438 (14.6) 610 (14.2) 0.5
Malignancy 1,320 (13.1) 317 (7.1) <0.0001
* p values from Chi-squared tests for differences in the percentage with the comorbidities between diabetic patients and non-diabetic patients
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disease or comorbidity). As would be expected, patients
with diabetes mellitus have higher rates of vascular
disease (20.4% compared to 7.5% in non-diabetics).
Similarly, ischaemic heart disease and cerebrovascular
disease were more common in diabetics. Smoking at
the time of initiation of RRT was similar for diabetics
and non-diabetics (table 6.7).
Haemoglobin concentration at the time of starting
RRT and comorbidity
The mean Hb prior to starting RRT in patients
recorded as starting RRT without any comorbidity
present was 10.3 g/dl compared to 10.2 g/dl for patients
with one or more comorbidities. Of patients without
any comorbidity, 57.1% achieved a Hb >10 g/dl
compared to 53.4% with one or more comorbidities.
Compared to those without any comorbidity, the mean
Hb concentrations at the start of RRT were lower in
patients with certain comorbidities, including malig-
nancy (10.0 g/dl, p¼<0.0001), a history of claudication
(10.0 g/dl, p¼<0.0001), ischaemic/neuropathic ulcers
(9.8 g/dl, p¼<0.0001) and amputation (9.8 g/dl,
p ¼ 0.0002). Although statistically significant, these Hb
differences at initiation of RRT do not appear clinically
significant.
Late presentation and comorbidity
Table 6.8 shows the referral time for patients with and
without various comorbidities. Patients with peripheral
vascular disease were more likely to be referred to a
nephrologist early and patients with malignancy were
more likely to be referred late. There was no association
between time of presentation and any other comorbidity.
Renal function at the time of starting RRT and
comorbidity
Table 6.9 shows the geometric mean eGFR prior to
starting RRT in patients with each of the individual
comorbidities. The (geometric) mean eGFR prior to
starting RRT in patients who were recorded as starting
without any comorbidity present was 7.6 ml/min/
1.73 m2. In each case, average eGFR was slightly higher
amongst patients with comorbidity compared to patients
without any comorbidity.
Age and comorbidity in patients by treatment
modality at start of RRT
All comorbidities were more prevalent in patients
receiving haemodialysis as their initial modality of
treatment rather than peritoneal dialysis (table 6.10).
This difference was statistically significant for all co-
morbid conditions other than previous CABG/coronary
angioplasty. The median age of patients with comor-
bidity data starting RRT on HD was 66.0 years compared
with 59.2 years for those starting PD (Kruskal Wallis test,
p < 0.0001). For each of the comorbid conditions, the
median age of patients on HD was higher than for
patients on PD (table 6.10).
Comorbidity and subsequent activation on deceased
donor transplant waiting list (TWL)
Table 6.11 shows that patients starting dialysis as their
first RRT modality who were activated on the TWL
within the first year, were younger and had significantly
less comorbidity at the start of RRT than those who were
not activated within the first year.
Table 6.8. Percentage prevalence of specific comorbidities amongst patients presenting late (0–89 days) compared with those present-
ing early (>89 days)
Late referral Early referral
Comorbidity N (%) N (%) p value*
Ischaemic heart disease 371 (23.0) 1,235 (24.5) 0.2
Cerebrovascular disease 166 (10.2) 524 (10.3) 0.9
Diabetes (not listed as PRD) 132 (8.2) 438 (8.8) 0.5
COPD 112 (6.9) 341 (6.8) 0.8
Liver disease 47 (2.9) 116 (2.3) 0.2
Peripheral vascular disease 173 (10.7) 685 (13.5) 0.003
Malignancy 294 (18.1) 528 (10.4) <0.0001
Smoking 265 (16.7) 768 (15.3) 0.2
* p values from Chi-squared tests for differences between referral groups in the percentage with the comorbidities
Comorbidity in UK RRT patients Nephron Clin Pract 2010;115(suppl1):c103–c116 c111
Comorbidity and survival within 90 days of starting
RRT
On univariate analysis stratified for age, most comor-
bidity was associated with an increased risk of death in
the first 90 days when compared with a patient in the
same age group without that comorbidity. This was
true amongst patients aged <65 years and those aged
565 years, the associations being more profound for
those aged <65 years (data not shown). Multivariable
stepwise Cox regression analyses stratified by age group
(<65 and 565) are shown in tables 6.12 and 6.13. As
identified in the univariate models, comorbidities in
younger patients were more indicative of early death
than when present in older patients. Diabetes did not
emerge as an independent predictor of death, probably
due to its close association with ischaemic heart disease
and peripheral vascular disease. Some comorbidities
may appear not to be associated with an increased risk
Table 6.9. eGFR within 2 weeks prior to the start of RRT by comorbidity 2003–2008
Comorbidity
eGFR geometric mean
(ml/min/1.73 m2)
eGFR
95% CI p value*
No comorbidity present 7.6 7.5–7.7 Ref
Any comorbidity present 8.3 8.2–8.4 <0.0001
Angina 8.7 8.5–8.8 <0.0001
MI in past 3 months 8.8 8.4–9.2 <0.0001
MI >3 months ago 8.7 8.6–8.9 <0.0001
CABG/angioplasty 9.1 8.9–9.4 <0.0001
Cerebrovascular disease 8.6 8.4–8.8 <0.0001
Diabetes (not listed as PRD) 8.5 8.3–8.7 <0.0001
Diabetes listed as PRD 8.7 8.5–8.8 <0.0001
COPD 8.5 8.3–8.8 <0.0001
Liver disease 8.3 7.8–8.7 0.003
Claudication 8.8 8.5–9.0 <0.0001
Ischaemic/neuropathic ulcers 8.8 8.4–9.1 <0.0001
Angioplasty/vascular graft 8.6 8.3–9.0 <0.0001
Amputation 8.9 8.4–9.3 <0.0001
Smoking 8.2 8.0–8.4 <0.0001
Malignancy 7.9 7.7–8.1 0.002
* Two-sample t-tests compare log(eGFR) for each comorbidity against those without comorbidity
Table 6.10. Number (and percentage) of incident patients with comorbid conditions starting PD and HD 2003–2008
HD PD
Comorbidity N (%) Median age N (%) Median age p value*
Angina 1,845 (16.9) 71.3 405 (11.6) 68.5 <0.0001
MI in past 3 months 339 (3.1) 70.7 51 (1.5) 69.1 <0.0001
MI >3 months ago 1,304 (11.9) 70.8 319 (9.1) 69.0 <0.0001
CABG/angioplasty 837 (7.7) 69.0 255 (7.3) 67.9 0.4
Cerebrovascular disease 1,177 (10.8) 71.1 230 (6.6) 66.4 <0.0001
Diabetes (not listed as PRD) 977 (9.1) 70.9 192 (5.5) 68.3 <0.0001
COPD 855 (7.9) 70.8 142 (4.1) 67.3 <0.0001
Liver disease 329 (3.0) 60.0 48 (1.4) 57.4 <0.0001
Claudication 957 (8.7) 70.6 180 (5.1) 67.5 <0.0001
Ischaemic/neuropathic ulcers 410 (3.7) 62.6 60 (1.7) 56.7 <0.0001
Angioplasty/vascular graft 411 (3.8) 71.4 90 (2.6) 70.1 0.001
Amputation 248 (2.3) 61.3 36 (1.0) 59.5 <0.0001
Smoking 1,629 (15.3) 61.2 441 (12.9) 55.3 0.001
Malignancy 1,457 (13.3) 72.0 232 (6.6) 70.1 <0.0001
* p values from Chi-squared tests for differences between modalities in the percentage with the comorbidities
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of death partly because of the low number of patients in
these groups and partly because those who had severe
disease and were thought likely not to survive 90 days,
may not be started on RRT (for instance, liver disease
in those aged565 years).
Comorbidity and survival 1 year after 90 days of
commencing RRT
Age and five comorbidities were independently
associated with an increased hazard of death within the
first year after 90 days for patients aged <65 years and
5 of these were among the 9 variables independently
associated with mortality beyond day 90 in patients
565 years (tables 6.14 and 6.15). Although diabetes
Table 6.11. Number (and percentage) of incident dialysis patients with comorbid conditions who were activated on the transplant
waiting list within one year of starting treatment compared to those patients who were not activated within one year of initiating RRT
Not activated on waiting list in first year Activated on waiting list in first year
Comorbidity N (%) Median age N (%) Median age p value*
Angina 1,849 (18.8) 71.3 86 (3.8) 57.9 <0.0001
MI in past 3 months 312 (3.2) 70.9 11 (0.5) 55.0 <0.0001
MI >3 months ago 1,287 (13.1) 71.0 48 (2.1) 58.9 <0.0001
CABG/angioplasty 818 (8.4) 69.3 57 (2.6) 58.4 <0.0001
Cerebrovascular disease 1,115 (11.3) 71.2 74 (3.3) 58.2 <0.0001
Diabetes (not cause of ERF) 895 (9.2) 71.1 65 (2.9) 54.6 <0.0001
COPD 773 (7.9) 71.1 51 (2.3) 57.9 <0.0001
Liver disease 270 (2.7) 60.1 37 (1.6) 54.6 0.002
Claudication 931 (9.4) 70.5 24 (1.1) 49.6 <0.0001
Ischaemic/neuropathic ulcers 373 (3.8) 63.4 24 (1.1) 45.1 <0.0001
Angioplasty/vascular graft 407 (4.1) 71.3 11 (0.5) 57.7 <0.0001
Amputation 218 (2.2) 61.3 13 (0.6) 52.0 <0.0001
Smoking 1,473 (15.4) 63.6 308 (13.8) 46.5 0.06
Malignancy 1,360 (13.8) 72.0 45 (2.0) 58.7 <0.0001
* p values from Chi-squared tests for differences between transplant waiting list groups in the percentage with the comorbidities
Table 6.12. Multivariate Cox proportional hazards model* for
predictors of death within the first 90 days of starting RRT
during 01/01/2003–30/09/2008: patients aged <65 years
Comorbidity Hazard ratio 95% CI p value
Malignancy 5.4 3.6–8.2 <0.0001
Liver disease 4.6 2.6–7.9 <0.0001
Amputation 4.4 2.3–8.3 <0.0001
Angina 2.1 1.3–3.3 0.001
Age (per 10 yrs) 1.5 1.2–1.9 <0.0001
* This is the result of a stepwise procedure. The variables considered
in the model were: age (in 10 year units) and the 14 comorbidity
variables except that ‘diabetes (not listed as PRD)’ and ‘diabetes
listed as PRD’ were replaced by ‘Diabetes of either category’.
Table 6.13. Multivariate Cox proportional hazards model* for
predictors of death within the first 90 days of starting RRT
during 01/01/2003–30/09/2008: patients aged565 years
Comorbidity
Hazard
ratio 95% CI p value
Ischaemic/neuropathic ulcers 2.4 1.6–3.5 <0.0001
MI in past 3 months 2.1 1.5–2.9 <0.0001
COPD 1.6 1.2–2.0 0.001
Age (per 10 yrs) 1.6 1.3–1.8 <0.0001
Angina 1.4 1.2–1.8 0.001
MI >3 months ago 1.4 1.1–1.8 0.004
Malignancy 1.4 1.1–1.8 0.003
* This is the result of a stepwise procedure. The variables considered
in the model were: age (in 10 year units) and the 14 comorbidity
variables except that ‘diabetes (not listed as PRD)’ and ‘diabetes
listed as PRD’ were replaced by ‘Diabetes of either category’.
Table 6.14. Multivariate Cox proportional hazards model* for
predictors of death in the year after the first 90 days of starting
RRT during 01/01/2003–30/09/2007: patients aged <65 years
Comorbidity
Hazard
ratio 95% CI p value
Malignancy 4.0 3.0–5.4 <0.0001
Ischaemic/neuropathic ulcers 2.5 1.7–3.7 <0.0001
Liver disease 2.2 1.4–3.4 0.0003
Diabetes of either category 1.8 1.4–2.3 <0.0001
Angina 1.4 1.0–1.9 0.03
Age (per 10 yrs) 1.3 1.2–1.5 <0.0001
* This is the result of a stepwise procedure. The variables considered
in the model were: age (in 10 year units) and the 14 comorbidity
variables except that ‘diabetes (not listed as PRD)’ and ‘diabetes
listed as PRD’ were replaced by ‘Diabetes of either category’.
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mellitus is independently associated with increased
mortality in patients <65 years but not in those aged
565 years, the opposite was true for smoking (tables
6.14 and 6.15).
Discussion
Comorbidity data completeness has been a cause for
concern since they were first reported by the UKRR in
1999 [14]. Worryingly, rates of completeness are decreas-
ing not increasing and the current rate of 40% in the UK
compares with rates of 85% in Canada, 95–100% in
Australia and New Zealand and 100% in the USA. How-
ever for the latter, the USRDS has a ‘tick if present’
policy, therefore no tick is interpreted as no comorbidity
but could also represent missing data. Some work has
recently been undertaken to learn from experience in
these countries [15]. Completeness should improve in
the future through a combination of linkage with other
secondary data sources (e.g. Hospital Episode Statistics
Dataset), statistical imputation techniques and local
governance pressures now that comorbidity items form
part of the National Renal Dataset. Caution must be
taken in interpreting the influence of comorbidity – in
at least one study patients with comorbidity recorded
have significantly better health outcomes than those
with missing comorbidity [16] so the generalisation of
findings from this selected group of patients cannot
therefore be assumed.
There are two recent reports that highlight the relative
contribution of comorbidity to survival analyses in renal
replacement patients. Van Manen and colleagues studied
the role of comorbidity on survival in over 15,000
incident RRT patients from five European countries
[17]. The addition of five comorbidities (diabetes melli-
tus, ischaemic heart disease, peripheral vascular disease,
cerebrovascular disease and malignancy) explained only
an additional 1.9% of the variance in survival on top
of the 14.4% explained by age, gender, PRD, treatment
modality and country. In the DOPPS study, 45 co-
morbidities were systematically recorded for over
15,000 prevalent HD patients and their relative contribu-
tion to survival over 3 years explored [18]. Total R2
increased from 0.13 to 0.17 upon the addition of the
most significant 17 conditions, in addition to demo-
graphic (age, gender, race), clinical (systolic blood pres-
sure, body mass index) and laboratory (Hb, albumin,
phosphate) variables. These studies highlight that our
routinely measured variables at present do not offer
good prediction of survival. The need for more complete
and perhaps novel comorbidity data goes beyond its role
in survival analyses as comorbidity is clearly relevant to
patients’ quality of life, the daily running of haemo-
dialysis units and performance in other areas such as
access to transplantation and achievement of permanent
vascular access.
An alternative approach to case-mix adjustment for
variations between centres in outcomes would be to
use information on the levels of comorbidity or life
expectancy in the general population served by a renal
centre, given that most renal centres in the UK have rela-
tively well-defined catchment areas. Such an approach
has been suggested for analyses comparing different
regions or countries [19, 20]. However, adjustment for
general population mortality as well as individual patient
comorbidity might risk over-adjustment and the catch-
ment areas of many centres would not show uniform
levels of general population life expectancy.
In the general population, the prevalence of cardio-
vascular disease increases exponentially with age, up to
and beyond 75 years of age [21]. This appears at odds
with the prevalence of cardiovascular disease in incident
RRT patients, which increases only modestly beyond
65–74 years of age (figure 6.2). In early reports from
the UKRR, the prevalence of cardiovascular disease was
lower in incident RRT patients aged 75þ compared to
those aged 65–74 [22]. One explanation for this paradox
is competing risk: poorer cardiovascular outcomes are
observed in patients with chronic kidney disease [23,
24], which may in part reflect lower use of medical
therapies that are of proven benefit [25]. Alternatively,
older patients with cardiovascular disease may be less
Table 6.15. Multivariate Cox proportional hazards model* for
predictors of death in the year after the first 90 days of starting
RRT during 01/01/2003–30/09/2007: patients aged565 years
Comorbidity
Hazard
ratio 95% CI p value
Liver disease 2.1 1.4–3.1 0.0003
Amputation 1.9 1.1–3.2 0.021
Malignancy 1.8 1.5–2.1 <0.0001
Age (per 10 yrs) 1.8 1.6–2.0 <0.0001
Ischaemic/neuropathic ulcers 1.6 1.1–2.4 0.011
Angina 1.5 1.3–1.7 <0.0001
COPD 1.3 1.1–1.7 0.008
Cerebrovascular disease 1.3 1.1–1.5 0.012
Smoking 1.2 1.0–1.5 0.048
* This is the result of a stepwise procedure. The variables considered
in the model were: age (in 10 year units) and the 14 comorbidity
variables except that ‘diabetes (not listed as PRD)’ and ‘diabetes
listed as PRD’ were replaced by ‘Diabetes of either category’.
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likely to be referred to a nephrologist for consideration of
RRT [26, 27] (though this may have become less true in
recent years [28]) or consider the benefits of dialysis over
supportive care less convincing [29].
Another initially paradoxical observation is the lower
(or equivalent) rate of vascular disease in South Asians
and Blacks despite higher rates of diabetes mellitus.
Rates of diabetes mellitus in ethnic groups commencing
RRT in the UK are consistent with general population
rates: in the English general population, compared to
Whites, the age-adjusted risk ratios for diabetes mellitus
range from 2.5 for Black Caribbean males to more than
5.0 for South Asians [30]. Considering the same general
population health survey data, age-adjusted risk ratios of
cardiovascular disease are only significantly higher for
Pakistani and Bangladeshi males and females and Black
Caribbean females (risk ratios 1.4–1.7) [30] and mor-
tality from ischaemic heart disease has been observed
to be lower for Blacks in the UK than Whites [31]. It is
also important to remember that the UKRR diabetes
mellitus and cardiovascular disease rates are not age-
adjusted and the age profile of the Black and South
Asian population in the UK also differs considerably
from that of the White population. Sixteen percent of
Whites are aged >65 compared with 6% of Blacks and
4% of South Asians [32], with incident non-White
RRT patients being significantly younger than their
White counterparts [33].
In these analyses, patients with comorbidity started
RRT at a higher eGFR than patients with no reported
comorbidity. This may suggest physicians advise patients
with a higher comorbidity burden to start dialysis earlier
or that these patients become symptomatic from their
ERF earlier than patients with no comorbidity. Current
evidence is conflicting as to whether starting dialysis at
a higher eGFR is associated with better survival [34,
35] or poorer outcomes [36, 37]. It may be that improved
survival associated with earlier start is just a reflection of
lead time bias [38]. Further, this analysis is open to
potential bias due to variability in the recording of
‘RRT start date’.
The lower Hb concentrations at start of RRT asso-
ciated with peripheral vascular disease and malignancies
could be due to diminished erythropoietin (EPO)
responsiveness or varying centre prescribing patterns
for EPO amongst patients with these comorbidities.
The lower Hb concentration associated with peripheral
vascular disease does not seem to be explained by late
referral or presentation, as these patients were referred
earlier compared to those without this comorbidity.
Patients who started HD were older and had more
comorbidity compared to those starting PD. These
findings probably reflect a perception amongst UK
healthcare practitioners and patients that PD is in
general more suitable for younger and fitter patients.
In addition, the presence of certain comorbid condi-
tions such as cerebrovascular disease, liver disease and
COPD can adversely affect the ability of patients to
perform PD exchanges or to tolerate large volumes of
dialysate in the peritoneum and hence influence the
choice of HD in these patients. Some centres in the UK
are starting to provide assisted PD (by a carer) which
may alter the distribution of treatment modalities in
the future.
The proportion of patients activated on the deceased
donor transplant waiting list is much less amongst
those with comorbidity compared to those without.
Hence, when time taken to activate patients on the trans-
plant waiting list is used as a marker of quality of care
provided by the centres, adjustments for differences in
comorbidity should be made for meaningful compari-
sons of the performance of each centre in listing patients
for a transplant.
There are important and at times counter-intuitive
associations between comorbidity and outcomes in
RRT patients with differences between ethnic groups
requiring further study. Individual comorbidity items
are each associated with significant hazards of death
and adjusting for this in centre (and international) com-
parisons must remain a priority.
Caution must also be taken when interpreting the
results of the multivariate survival analyses in which
smoking and diabetes are included alongside comor-
bidities which lie in the causal pathway (such as vascular
disease); adjusting for the vascular disease that has been,
in part, caused by the smoking or diabetes will attenuate
the association between these variables and survival. The
absence of an independent significant association
between smoking and survival (for example) should
not be interpreted as meaning that smoking does not
increase a dialysis patient’s risk of death. Indeed the
observation that almost 15% of new RRT patients start
dialysis as smokers is a major concern given the well
recognised excess cardiovascular risk that dialysis
patients have compared to those without CKD. Although
this figure is slowly reducing perhaps it is time to better
promote smoking cessation policies and guidance in
CKD clinics and renal centres across the UK.
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